Developer docs
API playgroundTry for free, no card

Search company profiles

IgG4ward! Foundation

Full company profile

uuid003mnu3

Namestring
IgG4ward! Foundation
Legal namestring
IgG4ward Foundation
Websiteurl
igg4ward.org
Company typeenum
Private
Founded yearint
2023
Descriptiontext

IgG4ward! Foundation is a 501(c)(3) non-profit patient advocacy organization founded in 2023 by Dr. John H. Stone, a rheumatologist at Massachusetts General Hospital and Harvard Medical School, dedicated exclusively to IgG4-Related Disease (IgG4-RD), a rare immune-mediated condition. The foundation serves two primary segments: patients and caregivers affected by IgG4-RD, and healthcare professionals involved in diagnosing and treating the disease. It operates as the only organization solely dedicated to IgG4-RD advocacy, research, and support, with a stated addressable population of approximately 40,000 diagnosed patients in the United States and hundreds of thousands globally.

The foundation's product portfolio centers on education, community connection, and clinical resource provision. Core digital assets include the IgG4ward! Community App for peer connection, the IgG4ME! App for medical history storage, and the IgG4ward! Academy — the first online education curriculum dedicated to IgG4-RD, scheduled to launch in May/June 2026. The foundation maintains a vetted Find a Doctor physician network, hosts Fireside Chat webinars, and runs in-person community events (BayJAM, EuroJAM, PeachJAM, CanJAM) plus the triennial International Symposium on IgG4-RD. Professional offerings include official Clinical Guidelines, research resources, and patient materials; the foundation directly influenced the MITIGATE Phase 3 trial with Amgen and contributes to clinical guideline development through its expert network.

The business model is donation- and sponsorship-based. Revenue streams include individual donations (preset tiers of $25, $100, $500, $1,000 plus custom amounts), corporate sponsorships from pharmaceutical and biotech companies (Amgen, Zenas BioPharma, Sanofi, Acepodia, Tellus BioVentures) and family foundations (The Moulder Family Foundation), and modest event registration fees ($500 per industry attendee for the International Symposium). All patient-facing services are provided free of charge. Geographic operations span the United States, Canada, the United Kingdom, Italy, Japan, and other countries through in-person events and a digital community platform available globally.

Short descriptiontext

IgG4ward! Foundation is a 501(c)(3) non-profit founded in 2023 by Dr. John Stone, dedicated to IgG4-Related Disease advocacy and support. It serves patients, caregivers, and healthcare professionals globally through digital apps, education programs, events, and a vetted physician network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease advocacy, patient education, community support, clinical guidelines, patient resources
Industry4 codes
PRIMARYHLAJAKAO
Global Health Advocacy, Policy & Rights Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYBPAMABAL
Health & Support Communities
Business & Public Services/Web, Mobile & Digital Platforms/Social Networks & Online Communities
SECONDARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Individual and Family Services6241
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Patient Advocacy Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Individual Donations
TypeGrants Donations
Description

Individual donors contribute financially to support the foundation's mission of education, research, awareness, and community programs for IgG4-RD patients and caregivers. Donation options include preset amounts ($25, $100, $500, $1,000) and custom amounts.

igg4ward.org
2Corporate Sponsorship
TypeGrants Donations
Description

Pharmaceutical and biotech companies (Amgen, Zenas BioPharma, Sanofi, Acepodia, Tellus BioVentures) provide sponsorship funding to support patient events, educational content, research initiatives, and community programs. Sponsorship tiers and benefits are available for companies interested in supporting the foundation.

igg4ward.org
3Event Revenue
TypeGrants Donations
Description

The foundation charges registration fees for certain professional events, such as the 6th International Symposium ($500 for industry registration with optional guest at $575).

igg4ward.org
Marketing channels13 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details3 tiers
1Free patient and caregiver services
ModelFreemiumBilling cadenceMonthly
Notes

All core services for patients and caregivers — community app, education, resources, Find a Doctor, Fireside Chats, patient events — are provided free of charge.

igg4ward.org
26th International Symposium - Industry Registration
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Industry registration: $500 per person; with guest: $575.

igg4ward.org
3Individual donations
ModelSubscriptionBilling cadenceMonthly
Notes

Donation options of $25, $100, $500, $1,000 or custom amounts. 3% processing fee for credit card transactions can be covered by donor.

igg4ward.org
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

IgG4ward! Foundation is a non-profit 501(c)(3) patient advocacy organization that provides education, community support, physician referrals, and advocacy resources exclusively for individuals affected by IgG4-Related Disease (IgG4-RD) and the healthcare professionals who treat them. It delivers these services through the IgG4ward! Academy (online education), community and medical history mobile apps, Fireside Chat webinars, in-person JAM events, the triennial International Symposium, official clinical guidelines, and a curated physician network.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Inebilizumab (Uplizna) reduced risk of IgG4-RD flare by 87% compared to standard treatment arm in the MITIGATE Phase 3 trial — the first FDA-approved drug for IgG4-RD (April 2025)
+3 more records
Product overview1 text field

IgG4ward! Foundation is a non-profit patient advocacy organization dedicated to IgG4-Related Disease (IgG4-RD), offering a portfolio of educational platforms, community tools, and professional resources. The core offerings include IgG4ward! Academy (a comprehensive online education curriculum launching in 2026), the IgG4ME! App for medical history storage, and the Community App for peer connection. Additional resources include Fireside Chats (expert webinars), a Physician Network for finding specialists, a Resource Library with videos and guides, Patient Stories, Clinical Trials information, and official Clinical Guidelines. The Foundation also hosts major events including International Symposiums and regional JAMs (Jamborees). The organization connects patients, caregivers, and healthcare professionals through education, advocacy, and community support.

Product and service2 records
1IgG4ward! Academy
CategoryEducation Platform
Description

The first-ever online education curriculum dedicated to IgG4-Related Disease, offering comprehensive lessons on disease overview, organ-specific manifestations, diagnosis, treatment, and day-to-day management in plain language for patients and caregivers.

2IgG4ME! App
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

IgG4ward! Foundation participated in the Arthritis Foundation's Commitment to a Cure Gala in Boston (September 2025), where Dr. John Stone was honored with the Marian Ropes Physician's Achievement Award. The partnership brings together the IgG4-RD and arthritis patient communities.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Amgen partnered with IgG4ward! to conduct the MITIGATE clinical trial — the first international clinical trial ever performed in IgG4-RD. The trial enrolled patients from 22 countries and demonstrated that inebilizumab reduced the risk of disease flare by 87%. This partnership led to the first FDA-approved treatment for IgG4-RD (inebilizumab/Uplizna) in April 2025. Amgen also provides ongoing sponsorship for patient events and educational initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Zenas BioPharma is a valued partner supporting the foundation's advocacy efforts and patient-centered initiatives, including international and U.S.-based in-person patient events (the JAMs). Their support fosters community engagement and provides opportunities for patients to connect and learn. Zenas also partnered with Bristol Myers Squibb for obexelimab development in IgG4-RD across Asia-Pacific markets.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Acepodia supports IgG4ward! Foundation through funding for patient-centered initiatives including the History of IgG4-RD film, CanJAM, PeachJAM, and the International Symposium on IgG4-RD. This support expands educational opportunities and strengthens connections across the IgG4-RD community.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Sanofi supports IgG4ward! through funding for educational and community initiatives including the History of IgG4-RD film, EuroJAM, and the International Symposium on IgG4-RD. These efforts support awareness and education and bring the global IgG4-RD community together.

6Bristol Myers Squibb
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Bristol Myers Squibb entered into a license and collaboration agreement with Zenas BioPharma to develop and commercialize obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. IgG4ward! is connected through its partnership with Zenas BioPharma, which is advancing the INDIGO Phase 3 trial in IgG4-RD.

igg4ward.org
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

The largest US umbrella rare-disease patient advocacy organization. Comparable as a 501(c)(3) that supports rare-disease communities, drives awareness, and runs educational programs — though it is broad rather than disease-specific like IgG4ward!.

2American Autoimmune Related Diseases Association (AARDA)
TypeBroad incumbent
Description

Advocacy organization for autoimmune diseases broadly. Comparable as a peer in autoimmune patient advocacy, education, and coalition-building across related diseases including IgG4-RD.

TypeDirect peer
Description

Single-disease patient advocacy nonprofit for lupus, an autoimmune disease. Comparable as a foundation providing education, community support, physician networks, and clinical-trial engagement for a specific immune-mediated condition.

TypeBroad incumbent
Description

Public policy advocacy nonprofit for the rare-disease community. Comparable as an advocacy and policy organization advancing rare-disease patient interests and funding research — overlaps in mission and donor/support base.

TypeDirect peer
Description

Rare-disease patient advocacy nonprofit. Comparable as an organization supporting rare-disease communities through education, advocacy, and corporate partnerships, with overlap in tools and patient-resource platforms.

TypeDirect peer
Description

Rare autoimmune patient advocacy organization. Highly comparable as a disease-specific foundation offering patient education, support groups, a physician network, and research funding for a rare rheumatologic/immune-mediated condition.

TypeDirect peer
Description

Single-disease nonprofit for Sjögren's disease, an autoimmune condition. Comparable as a disease-specific patient advocacy organization offering education, physician referrals, community events, and research support.

TypeDirect peer
Description

Single-disease patient advocacy foundation. Comparable model: disease-specific 501(c)(3) offering patient education, a physician network, community events, and pharmaceutical industry partnerships.

TypeBroad incumbent
Description

Major patient advocacy nonprofit in rheumatology/autoimmune disease space. Comparable as the organization that awarded Dr. Stone and as a peer in patient education, community events, and physician resources for autoimmune/immune-mediated diseases.

TypeBroad incumbent
Description

Professional society for rheumatologists. Comparable as the convener of clinical guidelines, continuing medical education, and research dissemination — areas where IgG4ward! shapes IgG4-RD clinical practice.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IgG4ward! Foundation

Patient Advocacy Servicesigg4ward.org

IgG4ward! Foundation is a 501(c)(3) non-profit founded in 2023 by Dr. John Stone, dedicated to IgG4-Related Disease advocacy and support. It serves patients, caregivers, and healthcare professionals globally through digital apps, education programs, events, and a vetted physician network.

What IgG4ward! Foundation does

IgG4ward! Foundation is a 501(c)(3) non-profit patient advocacy organization founded in 2023 by Dr. John H. Stone, a rheumatologist at Massachusetts General Hospital and Harvard Medical School, dedicated exclusively to IgG4-Related Disease (IgG4-RD), a rare immune-mediated condition. The foundation serves two primary segments: patients and caregivers affected by IgG4-RD, and healthcare professionals involved in diagnosing and treating the disease. It operates as the only organization solely dedicated to IgG4-RD advocacy, research, and support, with a stated addressable population of approximately 40,000 diagnosed patients in the United States and hundreds of thousands globally.

The foundation's product portfolio centers on education, community connection, and clinical resource provision. Core digital assets include the IgG4ward! Community App for peer connection, the IgG4ME! App for medical history storage, and the IgG4ward! Academy — the first online education curriculum dedicated to IgG4-RD, scheduled to launch in May/June 2026. The foundation maintains a vetted Find a Doctor physician network, hosts Fireside Chat webinars, and runs in-person community events (BayJAM, EuroJAM, PeachJAM, CanJAM) plus the triennial International Symposium on IgG4-RD. Professional offerings include official Clinical Guidelines, research resources, and patient materials; the foundation directly influenced the MITIGATE Phase 3 trial with Amgen and contributes to clinical guideline development through its expert network.

The business model is donation- and sponsorship-based. Revenue streams include individual donations (preset tiers of $25, $100, $500, $1,000 plus custom amounts), corporate sponsorships from pharmaceutical and biotech companies (Amgen, Zenas BioPharma, Sanofi, Acepodia, Tellus BioVentures) and family foundations (The Moulder Family Foundation), and modest event registration fees ($500 per industry attendee for the International Symposium). All patient-facing services are provided free of charge. Geographic operations span the United States, Canada, the United Kingdom, Italy, Japan, and other countries through in-person events and a digital community platform available globally.

IgG4ward! Foundation firmographics

Firmographics
Name
IgG4ward! Foundation
Legal name
IgG4ward Foundation
Website
https://igg4ward.org
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
IgG4ward! Foundation is a 501(c)(3) non-profit founded in 2023 by Dr. John Stone, dedicated to IgG4-Related Disease advocacy and support. It serves patients, caregivers, and healthcare professionals globally through digital apps, education programs, events, and a vetted physician network.
Ownership category
akta.pro rank

IgG4ward! Foundation industry classification

Industry
Product category
Patient Advocacy Services
NAICS
Voluntary Health Organizations (813212), Individual and Family Services (6241)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAJAKAO
Global Health Advocacy, Policy & Rights Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYBPAMABAL
Health & Support Communities
Business & Public Services/Web, Mobile & Digital Platforms/Social Networks & Online Communities
SECONDARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Rare disease advocacy
  • Patient education
  • Community support
  • Clinical guidelines
  • Patient resources

Where IgG4ward! Foundation is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

IgG4ward! Foundation business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Individual Donations: Individual donors contribute financially to support the foundation's mission of education, research, awareness, and community programs for IgG4-RD patients and caregivers. Donation options include preset amounts ($25, $100, $500, $1,000) and custom amounts.
  2. Corporate Sponsorship: Pharmaceutical and biotech companies (Amgen, Zenas BioPharma, Sanofi, Acepodia, Tellus BioVentures) provide sponsorship funding to support patient events, educational content, research initiatives, and community programs. Sponsorship tiers and benefits are available for companies interested in supporting the foundation.
  3. Event Revenue: The foundation charges registration fees for certain professional events, such as the 6th International Symposium ($500 for industry registration with optional guest at $575).

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree patient and caregiver services
One time/ perpetual licensePay-as-you-go6th International Symposium - Industry Registration
SubscriptionMonthlyIndividual donations

Go-to-market motion2 records

Distribution channels6 records

Marketing channels13 records

IgG4ward! Foundation product offering

Product offering

Core offering

IgG4ward! Foundation is a non-profit 501(c)(3) patient advocacy organization that provides education, community support, physician referrals, and advocacy resources exclusively for individuals affected by IgG4-Related Disease (IgG4-RD) and the healthcare professionals who treat them. It delivers these services through the IgG4ward! Academy (online education), community and medical history mobile apps, Fireside Chat webinars, in-person JAM events, the triennial International Symposium, official clinical guidelines, and a curated physician network.

Product overview

IgG4ward! Foundation is a non-profit patient advocacy organization dedicated to IgG4-Related Disease (IgG4-RD), offering a portfolio of educational platforms, community tools, and professional resources. The core offerings include IgG4ward! Academy (a comprehensive online education curriculum launching in 2026), the IgG4ME! App for medical history storage, and the Community App for peer connection. Additional resources include Fireside Chats (expert webinars), a Physician Network for finding specialists, a Resource Library with videos and guides, Patient Stories, Clinical Trials information, and official Clinical Guidelines. The Foundation also hosts major events including International Symposiums and regional JAMs (Jamborees). The organization connects patients, caregivers, and healthcare professionals through education, advocacy, and community support.

Differentiator

Problem solved

Functional benefit

Products and services

  • IgG4ward! Academy The first-ever online education curriculum dedicated to IgG4-Related Disease, offering comprehensive lessons on disease overview, organ-specific manifestations, diagnosis, treatment, and day-to-day management in plain language for patients and caregivers.
  • IgG4ME! App

Quantifiable outcome

  • Inebilizumab (Uplizna) reduced risk of IgG4-RD flare by 87% compared to standard treatment arm in the MITIGATE Phase 3 trial — the first FDA-approved drug for IgG4-RD (April 2025)
  • +3 more outcomes

Companies that use IgG4ward! Foundation

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

IgG4ward! Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

IgG4ward! Foundation partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor, flagship and core.

  • Arthritis FoundationminorStrategic or Co-development Partner · 1 September 2025IgG4ward! Foundation participated in the Arthritis Foundation's Commitment to a Cure Gala in Boston (September 2025), where Dr. John Stone was honored with the Marian Ropes Physician's Achievement Award. The partnership brings together the IgG4-RD and arthritis patient communities.
  • AmgenflagshipStrategic or Co-development Partner · 1 June 2024Amgen partnered with IgG4ward! to conduct the MITIGATE clinical trial — the first international clinical trial ever performed in IgG4-RD. The trial enrolled patients from 22 countries and demonstrated that inebilizumab reduced the risk of disease flare by 87%. This partnership led to the first FDA-approved treatment for IgG4-RD (inebilizumab/Uplizna) in April 2025. Amgen also provides ongoing sponsorship for patient events and educational initiatives.
  • Zenas BioPharmacoreStrategic or Co-development PartnerZenas BioPharma is a valued partner supporting the foundation's advocacy efforts and patient-centered initiatives, including international and U.S.-based in-person patient events (the JAMs). Their support fosters community engagement and provides opportunities for patients to connect and learn. Zenas also partnered with Bristol Myers Squibb for obexelimab development in IgG4-RD across Asia-Pacific markets.
  • AcepodiacoreGTM or Marketing PartnerAcepodia supports IgG4ward! Foundation through funding for patient-centered initiatives including the History of IgG4-RD film, CanJAM, PeachJAM, and the International Symposium on IgG4-RD. This support expands educational opportunities and strengthens connections across the IgG4-RD community.
  • SanoficoreGTM or Marketing PartnerSanofi supports IgG4ward! through funding for educational and community initiatives including the History of IgG4-RD film, EuroJAM, and the International Symposium on IgG4-RD. These efforts support awareness and education and bring the global IgG4-RD community together.
  • Bristol Myers SquibbminorStrategic or Co-development PartnerBristol Myers Squibb entered into a license and collaboration agreement with Zenas BioPharma to develop and commercialize obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. IgG4ward! is connected through its partnership with Zenas BioPharma, which is advancing the INDIGO Phase 3 trial in IgG4-RD.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

IgG4ward! Foundation competitors and assessment

Company assessment

Broad incumbents

  • National Organization for Rare Disorders (NORD): The largest US umbrella rare-disease patient advocacy organization. Comparable as a 501(c)(3) that supports rare-disease communities, drives awareness, and runs educational programs — though it is broad rather than disease-specific like IgG4ward!.
  • American Autoimmune Related Diseases Association (AARDA): Advocacy organization for autoimmune diseases broadly. Comparable as a peer in autoimmune patient advocacy, education, and coalition-building across related diseases including IgG4-RD.
  • EveryLife Foundation for Rare Diseases: Public policy advocacy nonprofit for the rare-disease community. Comparable as an advocacy and policy organization advancing rare-disease patient interests and funding research — overlaps in mission and donor/support base.
  • Arthritis Foundation: Major patient advocacy nonprofit in rheumatology/autoimmune disease space. Comparable as the organization that awarded Dr. Stone and as a peer in patient education, community events, and physician resources for autoimmune/immune-mediated diseases.
  • American College of Rheumatology (ACR): Professional society for rheumatologists. Comparable as the convener of clinical guidelines, continuing medical education, and research dissemination — areas where IgG4ward! shapes IgG4-RD clinical practice.

Direct peers

  • Lupus Foundation of America: Single-disease patient advocacy nonprofit for lupus, an autoimmune disease. Comparable as a foundation providing education, community support, physician networks, and clinical-trial engagement for a specific immune-mediated condition.
  • Global Genes: Rare-disease patient advocacy nonprofit. Comparable as an organization supporting rare-disease communities through education, advocacy, and corporate partnerships, with overlap in tools and patient-resource platforms.
  • Vasculitis Foundation: Rare autoimmune patient advocacy organization. Highly comparable as a disease-specific foundation offering patient education, support groups, a physician network, and research funding for a rare rheumatologic/immune-mediated condition.
  • Sjögren's Foundation: Single-disease nonprofit for Sjögren's disease, an autoimmune condition. Comparable as a disease-specific patient advocacy organization offering education, physician referrals, community events, and research support.
  • Pulmonary Fibrosis Foundation: Single-disease patient advocacy foundation. Comparable model: disease-specific 501(c)(3) offering patient education, a physician network, community events, and pharmaceutical industry partnerships.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

IgG4ward! Foundation social profiles

Digital presence

IgG4ward! Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IgG4ward! Foundation leadership team

Management profile

Number of profiles

Profiles2 records

IgG4ward! Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IgG4ward! Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IgG4ward! Foundation

What does IgG4ward! Foundation do?

IgG4ward! Foundation is a non-profit 501(c)(3) patient advocacy organization that provides education, community support, physician referrals, and advocacy resources exclusively for individuals affected by IgG4-Related Disease (IgG4-RD) and the healthcare professionals who treat them. It delivers these services through the IgG4ward! Academy (online education), community and medical history mobile apps, Fireside Chat webinars, in-person JAM events, the triennial International Symposium, official clinical guidelines, and a curated physician network.

Is IgG4ward! Foundation a public or private company?

IgG4ward! Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was IgG4ward! Foundation founded?

IgG4ward! Foundation was founded in 2023. It employs 1 to 10 people.

Where is IgG4ward! Foundation based?

IgG4ward! Foundation is headquartered in Boston, United States, in the North America region.

How does IgG4ward! Foundation make money?

Three revenue lines are on record. Individual Donations are the primary driver. The others are corporate Sponsorship and event Revenue.

Who are IgG4ward! Foundation's main competitors?

Broad incumbents on record are National Organization for Rare Disorders (NORD), American Autoimmune Related Diseases Association (AARDA), EveryLife Foundation for Rare Diseases, Arthritis Foundation and American College of Rheumatology (ACR). Direct peers are Lupus Foundation of America, Global Genes, Vasculitis Foundation, Sjögren's Foundation and Pulmonary Fibrosis Foundation.

Does IgG4ward! Foundation have an API?

No public API is recorded for IgG4ward! Foundation.

What industry is IgG4ward! Foundation in?

IgG4ward! Foundation's product category is Patient Advocacy Services. Its primary akta.pro industry code is HLAJAKAO, Global Health Advocacy, Policy & Rights Organizations, with a secondary code of BPAMABAL, Health & Support Communities. Its NAICS code is 813212 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales